Core Viewpoint - Kefu Medical plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence and brand recognition [1][3] Group 1: Company Overview - Kefu Medical specializes in the research, production, sales, and service of medical devices, covering health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine [1] - The company was listed on the A-share market in October 2021, achieving a net profit of approximately 429 million yuan that year [1] Group 2: International Expansion and Acquisitions - Kefu Medical has accelerated its internationalization through acquisitions, completing two projects in the first half of the year: Shanghai Huazhou and Ximan Na [1][3] - The company aims to enhance its overseas business capabilities and brand image through the issuance of H-shares [1][3] - The management indicated that the current policy environment supports companies going global, making the Hong Kong listing a strategic move [3] Group 3: Financial Performance - In 2024, Kefu Medical reported revenue of 2.983 billion yuan, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.6% [4] - The company experienced significant fluctuations in performance since its listing, with net profit dropping to approximately 254 million yuan in 2023 after a peak in 2021 [4] - In the first quarter of 2025, Kefu Medical's revenue declined by 8.59% to about 738 million yuan, and net profit fell by 9.68% to approximately 91.43 million yuan [4]
A股上市即业绩巅峰可孚医疗拟赴港IPO